{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:05:38Z","timestamp":1790715938042,"version":"4.1.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circulation"],"published-print":{"date-parts":[[2010,3,9]]},"abstract":"<jats:p>\n            <jats:bold>\n              <jats:italic>Background\u2014<\/jats:italic>\n            <\/jats:bold>\n            Statin therapy in women without cardiovascular disease (CVD) is controversial, given the insufficient evidence of benefit. We analyzed sex-specific outcomes in the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and synthesized the results with prior trials.\n          <\/jats:p>\n          <jats:p>\n            <jats:bold>\n              <jats:italic>Methods and Results\u2014<\/jats:italic>\n            <\/jats:bold>\n            JUPITER participants included 6801 women \u226560 years of age and 11 001 men \u226550 years of age with high-sensitivity C-reactive protein \u22652 mg\/L and low-density lipoprotein cholesterol &lt;130 mg\/dL randomized to rosuvastatin versus placebo. Meta-analysis studies were randomized placebo-controlled statin trials with predominantly or exclusively primary prevention in women and sex-specific outcomes (20 147 women; &gt;276 CVD events; mean age, 63 to 69 years). Absolute CVD rates (per 100 person-years) in JUPITER women for rosuvastatin and placebo (0.57 and 1.04, respectively) were lower than for men (0.88 and 1.54, respectively), with similar relative risk reduction in women (hazard ratio, 0.54; 95% confidence interval, 0.37 to 0.80;\n            <jats:italic>P<\/jats:italic>\n            =0.002) and men (hazard ratio, 0.58; 95% confidence interval, 0.45 to 0.73;\n            <jats:italic>P<\/jats:italic>\n            &lt;0.001). In women, there was significant reduction in revascularization\/unstable angina and nonsignificant reductions in other components of the primary end point. Meta-analysis of 13 154 women (240 CVD events; 216 total deaths) from exclusively primary prevention trials found a significant reduction in primary CVD events with statins by a third (relative risk, 0.63; 95% confidence interval, 0.49 to 0.82;\n            <jats:italic>P<\/jats:italic>\n            &lt;0.001;\n            <jats:italic>P<\/jats:italic>\n            for heterogeneity=0.56) with a smaller nonsignificant effect on total mortality (relative risk, 0.78; 95% confidence interval, 0.53 to 1.15;\n            <jats:italic>P<\/jats:italic>\n            =0.21;\n            <jats:italic>P<\/jats:italic>\n            for heterogeneity=0.20). Similar results were obtained for trials that were predominantly but not exclusively primary prevention.\n          <\/jats:p>\n          <jats:p>\n            <jats:bold>\n              <jats:italic>Conclusion\u2014<\/jats:italic>\n            <\/jats:bold>\n            JUPITER demonstrated that in primary prevention rosuvastatin reduced CVD events in women with a relative risk reduction similar to that in men, a finding supported by meta-analysis of primary prevention statin trials.\n          <\/jats:p>\n          <jats:p>\n            <jats:bold>\n              <jats:italic>Clinical Trial Registration\u2014<\/jats:italic>\n            <\/jats:bold>\n            URL: http:\/\/www.clinicaltrials.gov. Unique identifier: NCT00239681.\n          <\/jats:p>","DOI":"10.1161\/circulationaha.109.906479","type":"journal-article","created":{"date-parts":[[2010,2,23]],"date-time":"2010-02-23T03:46:58Z","timestamp":1266896818000},"page":"1069-1077","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":287,"title":["Statins for the Primary Prevention of Cardiovascular Events in Women With Elevated High-Sensitivity C-Reactive Protein or Dyslipidemia"],"prefix":"10.1161","volume":"121","author":[{"given":"Samia","family":"Mora","sequence":"first","affiliation":[{"name":"From the Center for Cardiovascular Disease Prevention, Divisions of Preventive Medicine (S.M., R.J.G., J.G.M., P.M.R.) and Cardiovascular Medicine (S.M., P.M.R.), Brigham and Women\u2019s Hospital, Harvard Medical School, and Department of Biostatistics, Harvard School of Public Health (R.J.G.), Boston, Mass; AstraZeneca, Philadelphia, Penn (J.H.); and McGill University Health Center, Montreal, Quebec, Canada (J.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Glynn","sequence":"additional","affiliation":[{"name":"From the Center for Cardiovascular Disease Prevention, Divisions of Preventive Medicine (S.M., R.J.G., J.G.M., P.M.R.) and Cardiovascular Medicine (S.M., P.M.R.), Brigham and Women\u2019s Hospital, Harvard Medical School, and Department of Biostatistics, Harvard School of Public Health (R.J.G.), Boston, Mass; AstraZeneca, Philadelphia, Penn (J.H.); and McGill University Health Center, Montreal, Quebec, Canada (J.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Hsia","sequence":"additional","affiliation":[{"name":"From the Center for Cardiovascular Disease Prevention, Divisions of Preventive Medicine (S.M., R.J.G., J.G.M., P.M.R.) and Cardiovascular Medicine (S.M., P.M.R.), Brigham and Women\u2019s Hospital, Harvard Medical School, and Department of Biostatistics, Harvard School of Public Health (R.J.G.), Boston, Mass; AstraZeneca, Philadelphia, Penn (J.H.); and McGill University Health Center, Montreal, Quebec, Canada (J.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean G.","family":"MacFadyen","sequence":"additional","affiliation":[{"name":"From the Center for Cardiovascular Disease Prevention, Divisions of Preventive Medicine (S.M., R.J.G., J.G.M., P.M.R.) and Cardiovascular Medicine (S.M., P.M.R.), Brigham and Women\u2019s Hospital, Harvard Medical School, and Department of Biostatistics, Harvard School of Public Health (R.J.G.), Boston, Mass; AstraZeneca, Philadelphia, Penn (J.H.); and McGill University Health Center, Montreal, Quebec, Canada (J.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Genest","sequence":"additional","affiliation":[{"name":"From the Center for Cardiovascular Disease Prevention, Divisions of Preventive Medicine (S.M., R.J.G., J.G.M., P.M.R.) and Cardiovascular Medicine (S.M., P.M.R.), Brigham and Women\u2019s Hospital, Harvard Medical School, and Department of Biostatistics, Harvard School of Public Health (R.J.G.), Boston, Mass; AstraZeneca, Philadelphia, Penn (J.H.); and McGill University Health Center, Montreal, Quebec, Canada (J.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M","family":"Ridker","sequence":"additional","affiliation":[{"name":"From the Center for Cardiovascular Disease Prevention, Divisions of Preventive Medicine (S.M., R.J.G., J.G.M., P.M.R.) and Cardiovascular Medicine (S.M., P.M.R.), Brigham and Women\u2019s Hospital, Harvard Medical School, and Department of Biostatistics, Harvard School of Public Health (R.J.G.), Boston, Mass; AstraZeneca, Philadelphia, Penn (J.H.); and McGill University Health Center, Montreal, Quebec, Canada (J.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_1_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39202.399942.AD"},{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39202.397488.AD"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60084-1"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.18.2243"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2008.08.001"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.21.2307"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.671826"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0807646"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000100688.17280.e6"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.19.2486"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-130-6-199903160-00002"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.319.7223.1492"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.20.1615"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.23.2998"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12948-0"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69472-5"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1089\/152460901317193549"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2007.122325"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)11600-X"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09327-3"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.01.039"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199511163332001"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(11)60993-2"}],"container-title":["Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIRCULATIONAHA.109.906479","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T05:53:41Z","timestamp":1715579621000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCULATIONAHA.109.906479"}},"subtitle":["Results From the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and Meta-Analysis of Women From Primary Prevention Trials"],"short-title":[],"issued":{"date-parts":[[2010,3,9]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,3,9]]}},"alternative-id":["10.1161\/CIRCULATIONAHA.109.906479"],"URL":"https:\/\/doi.org\/10.1161\/circulationaha.109.906479","relation":{},"ISSN":["0009-7322","1524-4539"],"issn-type":[{"value":"0009-7322","type":"print"},{"value":"1524-4539","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,9]]},"assertion":[{"value":"2010-02-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}